PTC Therapeutics Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Good afternoon, everyone. My name is Gena Wang. I'm a SMid-Cap Biotech analyst at the Barclays. It is my great pleasure to introduce our next presenting company, PTC Therapeutics. On the screen, on the Zoom with me, we have Matt Klein, Chief Development Officer. Also, we have Lisa Hayes, VP of Investor Relations.
With that, I hand over to Matt to give a slide presentation.
Thank you very much, Gena. It's great to have this opportunity to share an update on PTC's many exciting activities. This presentation will contain forward-looking statements.
For those of you who don't know PTC, we are a global commercial, diversified biopharmaceutical company focused on discovering, developing and commercializing innovative therapies to treat rare disorders.
PTC started in New Jersey 22 years ago as a small science-based company. And over the past few decades, we have built a robust global research,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |